CD19 and B-cell non-Hodgkin lymphoma: Furthermore, CD19 is a ubiquitously expressed antigen on the surface of B cells, including B-NHL.7,8,11 The most widespread and popular clinical treatment strategy is CAR-T cell therapy targeting CD19.34 In relapsed/refractory (R/R) aggressive B-cell NHLs, the CD19 marker in malignant cells is lost, necessitating alternative antigens for targeting these malignant cells.